Loading...
•
Mar 31, 2024
Harrow Q1 2024 Earnings Report
Announced first quarter 2024 financial results.
Key Takeaways
Harrow reported first quarter results, highlighting progress in key operational initiatives including building a dry eye disease franchise, expanding the retina franchise, and stabilizing ImprimisRx and Anterior Segment Products.
Focused on building a formidable dry eye disease franchise, including successfully launching VEVYE®.
Continued building a retina franchise with IHEEZO® and TRIESENCE®.
Stabilized ImprimisRx and Anterior Segment Products and returning them to a growth trajectory.
Well positioned to meet 2024 revenue guidance of more than $180 million.
Forward Guidance
Harrow is well positioned to meet its 2024 revenue guidance of more than $180 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...